Accentia Biopharmaceuticals Inc., of Tampa, Fla., appointed William Poole to its board of directors.

Agile Therapeutics Inc., of Princeton, N.J., named Lisa Flood associate director of regulatory and quality assurance.

Anesiva Inc., of South San Francisco, appointed James Campbell to its board of directors.

Bionovo Inc., of Emeryville, Calif., named Tom Chesterman senior vice president and chief financial officer.

Cell Therapeutics Inc., of Seattle, appointed Jay Umbreit medical director of the XYOTAX/CT-2103 program.

Cyclacel Pharmaceuticals Inc., of Berkeley Heights, N.J., named Gregory Reyes senior vice president of research.

DOR BioPharma Inc., of Miami, appointed Cyrille Buhrman to its board of directors.

Indevus Pharmaceuticals Inc., of Lexington, Mass., appointed Kurt Lewis senior vice president of sales and marketing.

InNexus Biotechnology Inc., of British Columbia, Canada, named Martin Weigert to its scientific advisory board.

Intellect Neurosciences Inc., of New York, appointed William Keane head of its audit committee. The company also named Keane and Elliot M. Maza to its board of directors.

MAP Pharmaceuticals Inc., of Mountain View, Calif., appointed Bernard Kelley to its board of directors.

Merrimack Pharmaceuticals Inc., of Cambridge, Mass., named Lisa Evren senior vice president and chief financial officer.

Metabolex Inc., of Hayward, Calif., elected Robert Chess to its board of directors.

Mymetics Corp., of Nyon, Switzerland, named Thomas Staehelin to its board of directors.

Naryx Pharma Inc., of Santa Barbara, Calif., appointed Andy Strayer vice president of clinical operations and medical affairs.